Memphasys Ltd - Asset Resilience Ratio

Latest as of June 2024: 0.00%

Memphasys Ltd (MEM) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

AU$12.43 Million
≈ $8.80 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Memphasys Ltd's Asset Resilience Ratio has changed over time. Check MEM PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Memphasys Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Memphasys Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Memphasys Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Memphasys Ltd Industry Peers by Asset Resilience Ratio

Compare Memphasys Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Novocure Ltd
NASDAQ:NVCR
Medical Devices 43.72%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
Medical Devices 10.88%
Bactiguard Holding AB (publ)
ST:BACTI-B
Medical Devices 8.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Anteris Technologies Global Corp
AU:AVR
Medical Devices 33.27%

Annual Asset Resilience Ratio for Memphasys Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Memphasys Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 0.00% AU$0.00
≈ $0.00
AU$12.43 Million
≈ $8.80 Million
--
2023-06-30 0.29% AU$42.75K
≈ $30.25K
AU$14.67 Million
≈ $10.38 Million
-4.49pp
2018-06-30 4.79% AU$201.81K
≈ $142.79K
AU$4.22 Million
≈ $2.98 Million
-47.63pp
2017-06-30 52.42% AU$3.83 Million
≈ $2.71 Million
AU$7.30 Million
≈ $5.17 Million
+51.82pp
2016-06-30 0.59% AU$42.74K
≈ $30.24K
AU$7.19 Million
≈ $5.09 Million
+0.04pp
2015-06-30 0.56% AU$38.00K
≈ $26.89K
AU$6.84 Million
≈ $4.84 Million
--
pp = percentage points

About Memphasys Ltd

AU:MEM Australia Medical Devices
Market Cap
$15.29 Million
AU$21.61 Million AUD
Market Cap Rank
#25901 Global
#1147 in Australia
Share Price
AU$0.01
Change (1 day)
-6.67%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more